Arthritis Rheumatol: Incidence of COVID-19 in patients with rheumatic disease sedatiat ingested immunosuppressants

The study was designed to describe the incidence and severity of 2019 coronavirus disease (COVID-19) in patients with rheumatoid diseases treated with synthetic or bio-anti-rheumatoid drugs (ts/bDMARDs) compared to the general population living in the same region of ItalyFrom 25 February 2020 to 10 April 2020, patients followed at the two tertiary rheumatism centres in Lombardy were invited to participate in a survey to identify confirmed patients with COVID-19, close contacts with known cases of COVID-19, infection symptoms, work, and changes in behaviour and disease treatment to prevent transmissionTHE INCIDENCE OF COVID-19 OF THE POPULATION OF LOMBARDY WAS OBTAINED FROM THE NATIONAL STATISTICAL OFFICECOVID-19 infection is determined by a nasopharyngeal swabA total of 955 patients (531 cases of rheumatoid arthritis, 203 cases of psoriasis, 181 cases of spinal arthritis and 40 cases of connective tissue disease/vascular inflammation/auto-inflammatory diseases; average age 53.7 years; women accounted for 67.4%)The response rate was 98.05 per centThe confirmed coVID-19 incidence was consistent with the general population (0.62% vs 0.66% ;p .92)No patients have serious complications or require intensive care, and all patients have temporarily suspended ongoing ts/bDMARDs treatmentAlmost all patients took preventive measures to prevent infection (90.6 per cent) and continued to use ts/bDMARDs (93.2%)89.5% of patients had stable disease activityAr's findings highlight the attitude of people with rheumatism to prevent infection while continuing chronic treatmentThe incidence and severity of COVID-19 in patients treated with ts/bDMARDs did not differ significantly from those in the general population in the same region